Literature DB >> 6752945

Monoclonal antibodies to novel myeloid antigens reveal human neutrophil heterogeneity.

E D Ball, R F Graziano, L Shen, M W Fanger.   

Abstract

Three cytotoxic murine monoclonal antibodies that recognize myeloid-specific antigens have been produced by immunization with normal human neutrophils or myeloblasts from a patient with acute myelomonocytic leukemia. Two of these, PMN 6 and PMN 29, are specific for neutrophils; the third monoclonal antibody, AML-2-23, is reactive with the majority of normal monocytes as well as a subpopulation of mature neutrophils. Although neutrophils from all individuals tested expressed these antigens, cytofluorographic analysis revealed that the percentage of cells bearing the PMN 6 and AML-2-23 antigens varied among individuals. Significant additional heterogeneity in the density of each antigen among antigen-bearing cells was also observed. All three antibodies efficiently mediated complement-dependent cytotoxicity of acute myelocytic leukemia cells yet were unreactive with lymphocytic leukemia cells. Neutrophil cytotoxicity was mediated by PMN 6 and PMN 29 but not by AML-2-23. On the other hand, AML-2-23, but not PMN 6 or PMN 29, was cytotoxic for normal monocytes and macrophages. These monoclonal antibodies may be of value in the study of normal neutrophil function and differentiation and may have clinical utility in diagnosis and therapy of myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6752945      PMCID: PMC346899          DOI: 10.1073/pnas.79.17.5374

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

3.  Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity.

Authors:  H P Koeffler; D W Golde
Journal:  Science       Date:  1978-06-09       Impact factor: 47.728

4.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Authors:  S J Collins; R C Gallo; R E Gallagher
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

5.  Cytochemical identification of monocytes and granulocytes.

Authors:  L T Yam; C Y Li; W H Crosby
Journal:  Am J Clin Pathol       Date:  1971-03       Impact factor: 2.493

6.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

7.  Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis.

Authors:  I M Goldstein; D Roos; H B Kaplan; G Weissmann
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

8.  Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose.

Authors:  P M Henson; Z G Oades
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

Review 9.  Classification of acute leukemia.

Authors: 
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

10.  Separation and functional characterization of human neutrophil subpopulations.

Authors:  M S Klempner; J I Gallin
Journal:  Blood       Date:  1978-04       Impact factor: 22.113

View more
  12 in total

1.  Glucocorticoid enhances gamma interferon effects on human monocyte antigen expression and ADCC.

Authors:  L Shen; P M Guyre; E D Ball; M W Fanger
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

2.  Widespread distribution in human tissues of an antigenic determinant of granulocytes.

Authors:  A J Howie; G Brown; A G Fisher; M Khan
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

3.  Gamma interferon induces monocytoid differentiation in the HL-60 cell line.

Authors:  E D Ball; P M Guyre; L Shen; J M Glynn; C R Maliszewski; P E Baker; M W Fanger
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

4.  Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2.

Authors:  R R Ingalls; E Lien; D T Golenbock
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Azurophilic granules of human neutrophils contain CD14.

Authors:  D A Rodeberg; R E Morris; G F Babcock
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

6.  Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14.

Authors:  M Arditi; J Zhou; R Dorio; G W Rong; S M Goyert; K S Kim
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 7.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

8.  Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide.

Authors:  E Ferrero; D Jiao; B Z Tsuberi; L Tesio; G W Rong; A Haziot; S M Goyert
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Two closely related antigens expressed on granulocytes, macrophages and some reticular elements in rat lymphoid tissues: characterization by monoclonal antibodies.

Authors:  Y Ishii; A Matsuura; H Iwaki; T Takami; K Kikuchi
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

10.  Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

Authors:  K D Sabbath; E D Ball; P Larcom; R B Davis; J D Griffin
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.